循环肿瘤DNA对复发/难治套细胞淋巴瘤缓解与结局的决定因素
研究对58例接受维奈克拉、来那度胺和利妥昔单抗治疗的复发/难治套细胞淋巴瘤患者进行ctDNA面板双重测序,发现SMARCA4突变者应答而TP53突变者耐药,治疗前ctDNA浓度与疾病特征和生存相关,动态ctDNA可补充临床缓解评估并揭示分子缓解患者的难治性,基线克隆性造血特征与血液学毒性和不良结局相关。
要点
- SMARCA4突变的复发/难治套细胞淋巴瘤对维奈克拉、来那度胺和利妥昔单抗治疗有应答,而TP53突变介导耐药。
- 治疗前ctDNA浓度与多项临床病理特征和生存相关,且独立于分子预测因素。
- 动态ctDNA监测可补充临床缓解评估,并揭示实时定量PCR判定分子缓解患者的难治性。
核心结论
- 研究报道了套细胞淋巴瘤ctDNA的新特征,揭示可能改变复发/难治套细胞淋巴瘤临床决策的微创工具。
研究设计与样本
- 研究对58例接受维奈克拉、来那度胺和利妥昔单抗治疗的复发/难治套细胞淋巴瘤患者进行ctDNA面板双重测序分析。
主要发现
- SMARCA4突变的复发/难治套细胞淋巴瘤对治疗有应答,而TP53突变介导耐药,这些分子预测因素独立于临床预后因素。
- 治疗前ctDNA捕获空间异质性,其浓度与多项临床病理疾病特征和生存相关,且独立于分子预测因素。
- 动态ctDNA微小残留病评估补充临床缓解评价,并揭示实时定量聚合酶链反应判定分子缓解患者的难治性。
- 基线克隆性造血特征与治疗期间血液学毒性及随访不良结局相关。
- 治疗期间TP53相关克隆性造血的正向选择未影响ctDNA缓解分析的特异性,片段化特征可区分套细胞淋巴瘤ctDNA与携带克隆性造血的无细胞DNA。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical tools to guide treatment decisions in relapsed/refractory mantle cell lymphoma (R/R MCL) are limited. Moreover, the translational potential of circulating tumor DNA (ctDNA) remains largely unproven. We designed and applied panel-based duplex sequencing of ctDNA to study molecular determinants of response and outcome in 58 patients with R/R MCL treated with venetoclax, lenalidomide, and rituximab. Genetic analysis revealed molecular predictors of response that were independent of clinical prognostic factors, with SMARCA4-mutated R/R MCLs responding to therapy, whereas TP53 mutations conferred resistance. Pretreatment ctDNA captured spatial heterogeneity, and its concentration was associated with multiple clinicopathological disease features and survival, independently of molecular predictors. Dynamic ctDNA assessment for minimal residual disease complemented clinical response evaluation and uncovered refractoriness in patients with molecular remission according to contemporary real-time quantitative polymerase chain reaction assay. Features of clonal hematopoiesis (CH) at baseline were associated with hematologic toxicity during treatment and poor outcomes on follow-up. Positive selection of TP53-related CH during treatment did not compromise the specificity of ctDNA response analysis, and fragmentation signatures allowed distinction between MCL ctDNA and CH-bearing cell-free DNA. Taken together, we report novel features in MCL ctDNA that reveal new minimally invasive tools that could potentially transform clinical decision-making in R/R MCL.
引用
- Meriranta L, Rask Kragh Jørgensen R, Pasanen A, et al. Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma. Blood Adv. 2025. PMID: 40402132. doi:10.1182/bloodadvances.2025015791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。